WO1993023075B1 - Traitement du syndrome de permeabilite capillaire diffuse et des maladies induites par la collagenase par administration d'inhibiteurs de la metalloproteinase matricielle - Google Patents
Traitement du syndrome de permeabilite capillaire diffuse et des maladies induites par la collagenase par administration d'inhibiteurs de la metalloproteinase matricielleInfo
- Publication number
- WO1993023075B1 WO1993023075B1 PCT/US1993/004542 US9304542W WO9323075B1 WO 1993023075 B1 WO1993023075 B1 WO 1993023075B1 US 9304542 W US9304542 W US 9304542W WO 9323075 B1 WO9323075 B1 WO 9323075B1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- collagenase
- compound
- bis
- compounds
- dioxopiperazine
- Prior art date
Links
- 102000029816 Collagenase Human genes 0.000 title claims abstract 19
- 108060005980 Collagenase Proteins 0.000 title claims abstract 19
- 229960002424 collagenase Drugs 0.000 title claims abstract 18
- 208000011580 syndromic disease Diseases 0.000 title claims abstract 12
- 230000002792 vascular Effects 0.000 title claims abstract 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims abstract 9
- 201000010099 disease Diseases 0.000 title claims 3
- 239000003771 matrix metalloproteinase inhibitor Substances 0.000 title 1
- 229940121386 matrix metalloproteinase inhibitor Drugs 0.000 title 1
- 238000000034 method Methods 0.000 claims abstract 35
- 150000001875 compounds Chemical class 0.000 claims abstract 30
- JTHRRMFZHSDGNJ-UHFFFAOYSA-N piperazine-2,3-dione Chemical class O=C1NCCNC1=O JTHRRMFZHSDGNJ-UHFFFAOYSA-N 0.000 claims abstract 8
- 206010051379 Systemic Inflammatory Response Syndrome Diseases 0.000 claims abstract 7
- 239000003475 metalloproteinase inhibitor Substances 0.000 claims abstract 7
- 206010040070 Septic Shock Diseases 0.000 claims abstract 6
- 208000035475 disorder Diseases 0.000 claims abstract 6
- 230000036303 septic shock Effects 0.000 claims abstract 6
- 108090000695 Cytokines Proteins 0.000 claims abstract 5
- 102000004127 Cytokines Human genes 0.000 claims abstract 5
- 239000002442 collagenase inhibitor Substances 0.000 claims abstract 4
- 230000000694 effects Effects 0.000 claims abstract 3
- 230000002401 inhibitory effect Effects 0.000 claims abstract 3
- 230000001225 therapeutic effect Effects 0.000 claims abstract 3
- 230000001988 toxicity Effects 0.000 claims abstract 3
- 231100000419 toxicity Toxicity 0.000 claims abstract 3
- 210000002966 serum Anatomy 0.000 claims abstract 2
- CYJAWBVQRMVFEO-UHFFFAOYSA-N piperazine-2,6-dione Chemical compound O=C1CNCC(=O)N1 CYJAWBVQRMVFEO-UHFFFAOYSA-N 0.000 claims 7
- 238000000099 in vitro assay Methods 0.000 claims 5
- 102100039364 Metalloproteinase inhibitor 1 Human genes 0.000 claims 4
- 102100026802 72 kDa type IV collagenase Human genes 0.000 claims 3
- 101710151806 72 kDa type IV collagenase Proteins 0.000 claims 3
- 102100030412 Matrix metalloproteinase-9 Human genes 0.000 claims 3
- 108010015302 Matrix metalloproteinase-9 Proteins 0.000 claims 3
- 101710170181 Metalloproteinase inhibitor Proteins 0.000 claims 3
- 229940126170 metalloproteinase inhibitor Drugs 0.000 claims 3
- 101000645291 Bos taurus Metalloproteinase inhibitor 2 Proteins 0.000 claims 2
- 229940122097 Collagenase inhibitor Drugs 0.000 claims 2
- 101000669513 Homo sapiens Metalloproteinase inhibitor 1 Proteins 0.000 claims 2
- 108010052285 Membrane Proteins Proteins 0.000 claims 2
- 102100026262 Metalloproteinase inhibitor 2 Human genes 0.000 claims 2
- 108010031374 Tissue Inhibitor of Metalloproteinase-1 Proteins 0.000 claims 2
- 108010031372 Tissue Inhibitor of Metalloproteinase-2 Proteins 0.000 claims 2
- 210000002469 basement membrane Anatomy 0.000 claims 2
- 238000000338 in vitro Methods 0.000 claims 2
- XSCHRSMBECNVNS-UHFFFAOYSA-N quinoxaline Chemical compound N1=CC=NC2=CC=CC=C21 XSCHRSMBECNVNS-UHFFFAOYSA-N 0.000 claims 2
- JGQGCJKPBAYEHO-UHFFFAOYSA-N 1-(morpholin-4-ylmethyl)-4-[2-[4-(morpholin-4-ylmethyl)-3,5-dioxopiperazin-1-yl]ethyl]piperazine-2,6-dione Chemical compound C1C(=O)N(CN2CCOCC2)C(=O)CN1CCN(CC1=O)CC(=O)N1CN1CCOCC1 JGQGCJKPBAYEHO-UHFFFAOYSA-N 0.000 claims 1
- MAUYWACILHVRLR-UHFFFAOYSA-N 1-(morpholin-4-ylmethyl)-4-[2-[4-(morpholin-4-ylmethyl)-3,5-dioxopiperazin-1-yl]propyl]piperazine-2,6-dione Chemical compound C1C(=O)N(CN2CCOCC2)C(=O)CN1C(C)CN(CC1=O)CC(=O)N1CN1CCOCC1 MAUYWACILHVRLR-UHFFFAOYSA-N 0.000 claims 1
- 238000007809 Boyden Chamber assay Methods 0.000 claims 1
- 239000003298 DNA probe Substances 0.000 claims 1
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 claims 1
- 108010002352 Interleukin-1 Proteins 0.000 claims 1
- 108010002350 Interleukin-2 Proteins 0.000 claims 1
- 230000037396 body weight Effects 0.000 claims 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 claims 1
- 239000002975 chemoattractant Substances 0.000 claims 1
- -1 cyclopropanediyl Chemical class 0.000 claims 1
- 125000000524 functional group Chemical group 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- 238000001727 in vivo Methods 0.000 claims 1
- 230000009545 invasion Effects 0.000 claims 1
- 125000001064 morpholinomethyl group Chemical group [H]C([H])(*)N1C([H])([H])C([H])([H])OC([H])([H])C1([H])[H] 0.000 claims 1
- 230000004899 motility Effects 0.000 claims 1
- 102000040430 polynucleotide Human genes 0.000 claims 1
- 108091033319 polynucleotide Proteins 0.000 claims 1
- 239000002157 polynucleotide Substances 0.000 claims 1
- BMKDZUISNHGIBY-UHFFFAOYSA-N razoxane Chemical compound C1C(=O)NC(=O)CN1C(C)CN1CC(=O)NC(=O)C1 BMKDZUISNHGIBY-UHFFFAOYSA-N 0.000 claims 1
- 229960000460 razoxane Drugs 0.000 claims 1
- 239000000523 sample Substances 0.000 claims 1
- 230000003381 solubilizing effect Effects 0.000 claims 1
- 208000020446 Cardiac disease Diseases 0.000 abstract 1
- 102000005741 Metalloproteases Human genes 0.000 abstract 1
- 108010006035 Metalloproteases Proteins 0.000 abstract 1
- 208000006011 Stroke Diseases 0.000 abstract 1
- 230000033115 angiogenesis Effects 0.000 abstract 1
- 206010003246 arthritis Diseases 0.000 abstract 1
- 208000019622 heart disease Diseases 0.000 abstract 1
Abstract
Méthode permettant d'identifier les patients risquant d'être atteints du syndrome de perméabilité capillaire diffuse et d'un syndrome de réaction inflammatoire systémique tel que le choc septique, en déterminant les taux de sérum d'expression de métalloprotéinase, en particulier d'expressions de collagénase de type IV. Méthode de traitement ou de prévention du syndrome de perméabilité diffuse et des syndromes de réaction inflammatoire systémique par administration d'un ou plusieurs inhibiteurs de métalloprotéinase, de préférence d'inhibiteurs de collagénase de type IV. En outre, l'efficacité thérapeutique des composés bis(dioxopiperazine) est déterminée sur la base de l'activité inhibitrice de la collagénase, et les composés inhibant l'activité de la collagénase sont utilisés pour le traitement des désordres liés à la collagénase, par exemple le syndrome de perméabilité capillaire diffuse, le choc septique, l'ictus, les désordres cardiaques, l'angionénèse et l'arthrite. Enfin, méthode de prévention ou de traitement de la toxicité résultant de l'expression de la cytokine endogène ou d'administration de cytokine par administration d'un ou plusieurs inhibiteurs de métalloprotéinase, de préférence d'inhibiteurs de collagénase de type IV.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP93913865A EP0642353A1 (fr) | 1992-05-14 | 1993-05-14 | Traitement du syndrome de permeabilite capillaire diffuse et des maladies induites par la collagenase par administration d'inhibiteurs de la metalloproteinase matricielle |
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US88285592A | 1992-05-14 | 1992-05-14 | |
| US882,855 | 1992-05-14 | ||
| US99790492A | 1992-12-29 | 1992-12-29 | |
| US997,904 | 1992-12-29 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO1993023075A1 WO1993023075A1 (fr) | 1993-11-25 |
| WO1993023075B1 true WO1993023075B1 (fr) | 1994-01-06 |
Family
ID=27128675
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/US1993/004542 WO1993023075A1 (fr) | 1992-05-14 | 1993-05-14 | Traitement du syndrome de permeabilite capillaire diffuse et des maladies induites par la collagenase par administration d'inhibiteurs de la metalloproteinase matricielle |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US5866570A (fr) |
| EP (1) | EP0642353A1 (fr) |
| AU (1) | AU4373993A (fr) |
| WO (1) | WO1993023075A1 (fr) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5892112A (en) * | 1990-11-21 | 1999-04-06 | Glycomed Incorporated | Process for preparing synthetic matrix metalloprotease inhibitors |
| US20030203976A1 (en) | 1993-07-19 | 2003-10-30 | William L. Hunter | Anti-angiogenic compositions and methods of use |
| DK1159974T3 (da) * | 1993-07-19 | 2007-11-26 | Angiotech Pharm Inc | Antiangiogene sammensætninger indeholdende taxol og en ikke-bionedbrydelig bærer og deres anvendelse |
| US5641636A (en) * | 1994-05-20 | 1997-06-24 | University Of Pennsylvania | Method of predicting fetal membrane rupture based on matrix metalloproteinase-9 activity |
| US6140099A (en) * | 1994-05-20 | 2000-10-31 | The Trustees Of The University Of Pennsylvania | Method of delaying fetal membrane rupture by inhibiting matrix metalloproteinase-9 activity |
| US5688781A (en) * | 1994-08-19 | 1997-11-18 | Bristol-Myers Squibb Company | Method for treating vascular leak syndrome |
| US5840698A (en) * | 1994-10-27 | 1998-11-24 | Affymax Technologies N.V. | Inhibitors of collagenase-1 and stormelysin-I metalloproteases, pharmaceutical compositions comprising same and methods of their use |
| US5831004A (en) | 1994-10-27 | 1998-11-03 | Affymax Technologies N.V. | Inhibitors of metalloproteases, pharmaceutical compositions comprising same and methods of their use |
| US5905027A (en) * | 1995-12-27 | 1999-05-18 | Uab Research Foundation | Method of diagnosing and treating gliomas |
| US6541214B1 (en) * | 1998-11-13 | 2003-04-01 | Oregon Heath Science University | N-terminally truncated HER-2/neu protein as a cancer prognostic indicator |
| MXPA01009212A (es) | 1999-03-12 | 2004-04-23 | Topotarget As | Tratamiento de la extravasacion accidental de antraciclinas. |
| JP4070409B2 (ja) * | 1999-05-24 | 2008-04-02 | 塩野義製薬株式会社 | マトリックスメタロプロテアーゼ阻害活性の評価方法 |
| US6294694B1 (en) | 1999-06-04 | 2001-09-25 | Wisconsin Alumni Research Foundation | Matrix metalloproteinase inhibitors and method of using same |
| CA2389751A1 (fr) * | 1999-11-01 | 2001-05-10 | Curagen Corporation | Genes exprimes de maniere differentielle impliques dans l'angiogenese, polypeptides codes par lesdits genes, et techniques d'utilisation de ces genes |
| US6800298B1 (en) | 2000-05-11 | 2004-10-05 | Clemson University | Biological lubricant composition and method of applying lubricant composition |
| FR2823440B1 (fr) * | 2000-11-14 | 2004-06-04 | Pharmascience Lab | Composition pharmaceutique ou cosmetique ainsi que l'utilisation d'au moins un compose actif pour inhiber la migration des cellules de langerhans |
| FR2823117A1 (fr) * | 2000-11-14 | 2002-10-11 | Pharmascience Lab | Composition pharmaceutique ou cosmetique ainsi que l'utilisation d'au moins un compose actif pour inhiber la migration des cellules de langerhans |
| AU2002235692A1 (en) * | 2001-02-23 | 2002-09-04 | Biophage Inc. | Methods and compositions for preventing and treating neutrophil-mediated diseases |
| US20030181371A1 (en) * | 2001-12-28 | 2003-09-25 | Angiotech Pharmaceuticals, Inc. | Compositions and methods of using collajolie |
| US20060088899A1 (en) * | 2002-05-31 | 2006-04-27 | Alvarez Vernon L | Combination chemotherapy with chlorotoxin |
| CA2509060A1 (fr) * | 2002-12-27 | 2004-07-22 | Angiotech International Ag | Compositions et procedes d'utilisation de collajolie |
| US7407660B2 (en) | 2003-04-16 | 2008-08-05 | Genentech, Inc. | Methods and compositions for selective modulation of vascularization |
| BRPI0400284A (pt) * | 2004-03-18 | 2005-11-01 | Fundacao Oswaldo Cruz | Uso de dm 43 e seus fragmentos como inibidor de metaloproteases de matriz |
| US7622593B2 (en) | 2006-06-27 | 2009-11-24 | The Procter & Gamble Company | Human protein tyrosine phosphatase inhibitors and methods of use |
| US7589212B2 (en) * | 2006-06-27 | 2009-09-15 | Procter & Gamble Company | Human protein tyrosine phosphatase inhibitors and methods of use |
| US8849577B2 (en) | 2006-09-15 | 2014-09-30 | Metabolon, Inc. | Methods of identifying biochemical pathways |
| BRPI0912683A2 (pt) | 2008-05-15 | 2016-01-26 | Transmolecular Inc | tratamento de tumores metastáticos |
| WO2011097533A1 (fr) | 2010-02-04 | 2011-08-11 | Transmolecular, Inc. | Polypeptides chlorotoxines et leurs conjugués et utilisations |
| CN103097403B (zh) | 2010-05-11 | 2017-04-19 | 弗雷德哈钦森癌症研究中心 | 氯毒素变体、缀合物及其使用方法 |
| SG11201504600UA (en) | 2012-12-10 | 2015-07-30 | Hutchinson Fred Cancer Res | Methods for screening |
| US11559580B1 (en) | 2013-09-17 | 2023-01-24 | Blaze Bioscience, Inc. | Tissue-homing peptide conjugates and methods of use thereof |
| CA3021011A1 (fr) | 2016-04-15 | 2017-10-19 | Blaze Bioscience, Inc. | Methodes de traitement du cancer du sein |
| EP3482758A1 (fr) * | 2017-11-10 | 2019-05-15 | Universite De Montpellier | Nouvelles utilisations de composés lipophénoliques |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4276284A (en) * | 1971-07-26 | 1981-06-30 | Brown Stuart I | Prevention of collagenase induced disease by treatment with collagenase inhibitors |
| US4950755A (en) * | 1985-08-12 | 1990-08-21 | Ohio State University | Bis(morpholinomethyl) derivative of 1,2-bis(dioxopiperizinyl)propane |
| US5270447A (en) * | 1988-05-20 | 1993-12-14 | The United States Of America As Represented By The Department Of Health & Human Services | Metalloproteinase peptides: role in diagnosis and therapy |
| US5189178A (en) * | 1990-11-21 | 1993-02-23 | Galardy Richard E | Matrix metalloprotease inhibitors |
-
1993
- 1993-05-14 WO PCT/US1993/004542 patent/WO1993023075A1/fr active Application Filing
- 1993-05-14 AU AU43739/93A patent/AU4373993A/en not_active Abandoned
- 1993-05-14 EP EP93913865A patent/EP0642353A1/fr not_active Withdrawn
-
1994
- 1994-06-21 US US08/262,888 patent/US5866570A/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO1993023075B1 (fr) | Traitement du syndrome de permeabilite capillaire diffuse et des maladies induites par la collagenase par administration d'inhibiteurs de la metalloproteinase matricielle | |
| Foulds et al. | Pharmacokinetics of sulbactam in humans | |
| US5880124A (en) | Blocking induction of tetrahydrobiopterin to block induction of nitric oxide synthesis | |
| Werkheiser | The biochemical, cellular, and pharmacological action and effects of the folic acid antagonists | |
| Simons et al. | The pharmacokinetics and antihistaminic of the H1 receptor antagonist hydroxyzine | |
| Hall et al. | Substituted cyclic imides as potential anti-gout agents | |
| Gukovsky et al. | A rat model reproducing key pathological responses of alcoholic chronic pancreatitis | |
| EA003616B1 (ru) | Компоненты, улучшающие кожную проницаемость | |
| CA2163211A1 (fr) | Inhibition du facteur inhibiteur de la migration dans le traitement de maladies avec manifestation de toxicite via la cytokine | |
| US20100004327A1 (en) | Novel Use of Ansamycin Antibiotics And Method of Screening Novel Angiogenesis Inhibitor | |
| Kirch et al. | The influence of renal function on clinical pharmacokinetics of moxonidine | |
| ES2565609T3 (es) | Tratamiento de enfermedades asociadas al uso de antibióticos | |
| US5069895A (en) | Methods for the treatment of alcohol intoxication and dependence | |
| Kuang et al. | Combination of sildenafil and simvastatin ameliorates monocrotaline-induced pulmonary hypertension in rats | |
| Lavigne et al. | The N-formylpeptide receptor (FPR) and a second Gi-coupled receptor mediate fMet–Leu–Phe-stimulated activation of NADPH oxidase in murine neutrophils | |
| Yoo et al. | Rapid microsample analysis of imipramine and desipramine by reversed-phase high-performance liquid chromatography with ultraviolet detection | |
| Shimokawa et al. | Neurotoxic Convulsions Induced by Histamine H2Receptor Antagonists in Mice | |
| Dorr et al. | Interaction of cimetidine but not ranitidine with cyclophosphamide in mice | |
| Goering et al. | Comparison of BL-S786 with cephalothin, cefamandole and cefoxitin in vitro and in treatment of experimental infections in mice | |
| Weihrauch et al. | Cerebral toxicity of penicillins in relation to their hydrophobic character | |
| EP0504290B1 (fr) | Inhibiteurs de reductase de dihydrofolate de pneumocystis carinii | |
| Davis et al. | Evaluation of chemotherapeutic agents in mammary carcinoma induced by 3-methylcholanthrene in Wistar rats | |
| Meyers et al. | Pharmacokinetics of cefoperazone in ambulatory elderly volunteers compared with young adults | |
| Sinnige et al. | Phase I–II study of the addition of α-2a interferon to 5-fluorouracil/leucovorin. Pharmacokinetic interaction of α-2a interferon and leucovorin | |
| KR100445640B1 (ko) | 부테인의 간경화 및 간섬유증 치료제 조성물 |